dr. polsky on the clinical validity of ctdna in braf-mutant melanoma
Published 4 years ago • 79 plays • Length 1:02Download video MP4
Download video MP3
Similar videos
-
2:06
dr. polsky on the predictive value of ctdna in braf-mutant melanoma
-
1:22
dr. polsky on validating ctdna as a biomarker in braf-mutant melanoma
-
1:12
dr. polsky on the association between ctdna and survival in melanoma
-
0:57
dr. polsky on potential applications of ctdna in melanoma
-
1:13
dr. polsky on using ctdna as a biomarker for melanoma
-
0:55
dr. polsky on the unmet need of clinical utility in liquid biopsy
-
20:34
role of circulating tumor cells/dna & liquid biopsy in melanoma - david polsky
-
0:59
how physicians can detect ctdna in melanoma
-
1:32
dr. pavlick on sequencing challenges with braf-mutant melanoma
-
2:19
dr. robert on 5-year analysis of dabrafenib/trametinib in braf v600-mutant melanoma
-
1:19
expert discusses mutations in melanoma
-
4:01
potential use of ctdna and mrd in crc
-
1:15
biomarkers being explored in hodgkin lymphoma: the role of ctdna
-
2:13
dr. bach on examining ctdna in crc
-
0:40
expanding the use of ctdna in clinical trials
-
3:05
the clinical use of circulating tumor dna in t-cell lymphomas
-
2:10
improving risk stratification & treatment decisions for dlbcl: ctdna & the ipi
-
1:28
the remaining hurdles for using ctdna in lymphoma
-
1:51
a positive ctdna test after adjuvant therapy: 2023 best of gi